GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi India Ltd (NSE:SANOFI) » Definitions » Tax Expense

Sanofi India (NSE:SANOFI) Tax Expense : ₹2,426 Mil (TTM As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Sanofi India Tax Expense?

Sanofi India's tax expense for the months ended in Dec. 2023 was ₹511 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2023 was ₹2,426 Mil.


Sanofi India Tax Expense Historical Data

The historical data trend for Sanofi India's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi India Tax Expense Chart

Sanofi India Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,857.00 1,996.00 3,132.00 2,437.00 2,426.00

Sanofi India Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 595.00 731.00 605.00 579.00 511.00

Sanofi India Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2,426 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sanofi India  (NSE:SANOFI) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Sanofi India Tax Expense Related Terms

Thank you for viewing the detailed overview of Sanofi India's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Sanofi India (NSE:SANOFI) Business Description

Traded in Other Exchanges
Address
Saki Vihar Road, Sanofi House, CTS Number 117-B, L&T Business Park, Powai, Mumbai, MH, IND, 400072
Sanofi India Ltd is a drug manufacturing company that focuses on a range of therapeutic areas, including Diabetes, Cardiology, Consumer Healthcare, Hospital, Central Nervous System, and Anti-Histamines. The company's diabetes presence includes oral anti-diabetic products and insulin. The consumer healthcare area also maintains a nutraceutical portfolio. The company's export markets include Germany, the U.K., Australia, and Russia. The company utilizes strategic partnerships as a component of its growth strategy.

Sanofi India (NSE:SANOFI) Headlines

No Headlines